U.S. Medical Equipment Stock News

NYSE:AIG
NYSE:AIGInsurance

American International Group (AIG) Could Be 11% Undervalued As Q2 Earnings Slip

American International Group (AIG) has drawn fresh attention after reporting second quarter 2026 results that showed slightly lower revenue and net income. Earnings per share also softened compared with the same period last year. See our latest analysis for American International Group. At a share price of $78.78, American International Group has seen its short term share price performance soften, with the 1 day and year to date share price returns both declining. At the same time, the 1 year...
NYSE:ESAB
NYSE:ESABMachinery

Will Record Sales, Eddyfi Deal and Raised 2026 Outlook Change ESAB's (ESAB) Margin Narrative?

ESAB Corporation recently reported its second-quarter 2026 results, with sales rising to US$807.63 million from US$715.59 million a year earlier, while net income fell to US$32.35 million from US$66.88 million. Alongside record sales and an earnings miss, ESAB closed the Eddyfi acquisition ahead of schedule and raised its 2026 outlook, tying short-term margin pressure to what management describes as stronger long-term demand and expanded technology capabilities. We’ll now examine how ESAB’s...
NYSE:CYD
NYSE:CYDMachinery

Did Stronger H1 Earnings and Genset IPO Plans Just Shift China Yuchai International's (CYD) Investment Narrative?

China Yuchai International Limited recently reported half-year 2026 results showing sales of CNY 14,666.43 million and net income of CNY 560.6 million, both higher than a year earlier, with basic earnings per share from continuing operations rising to CNY 14.94. Investors are also focusing on the company’s push into high-horsepower and alternative-fuel engines, including marine, power generation, and AI data-center applications, alongside a planned Hong Kong IPO for its genset power...
NYSE:TTI
NYSE:TTIEnergy Services

TETRA Technologies (TTI) Could Be 32% Below Fair Value After Arkansas Bromine Approval

Why the latest earnings matter for TETRA Technologies stock TETRA Technologies (TTI) has become a focus for investors after its second quarter earnings on 3 August 2026, which paired revenue and EBITDA growth with a final go ahead for the Arkansas bromine project. See our latest analysis for TETRA Technologies. Over the past year TETRA Technologies has delivered a very strong 1 year total shareholder return of 117.09%. However, the share price is down 16.40% over 3 months and 9.95% over 30...
NYSE:KMI
NYSE:KMIOil and Gas

Is Kinder Morgan (KMI) Undervalued After Its New Bond Offerings?

Why Kinder Morgan stock is back in focus after new bond offerings Kinder Morgan (KMI) recently completed several fixed income offerings, including senior unsecured fixed rate notes with attached guarantees. These new bonds give investors fresh information about the company’s funding mix and balance sheet decisions. The transactions include US$595.782 million of 6.150% notes due August 1, 2056 and US$1.149138 billion of 5.550% notes due August 1, 2036. Both sets of notes are senior, unsecured,...
NYSE:IT
NYSE:ITIT

Gartner (IT) Is Back In Focus After Fresh Guidance, But Does Valuation Still Look Rich?

Why Gartner Stock Is Back in Focus After Fresh Guidance Gartner (IT) is back on investor watch after issuing updated full year 2026 guidance alongside second quarter results. The company now expects revenue of at least $6.375b on an FX neutral growth rate of 1%. The company also reported June quarter earnings and progress on a long running share repurchase program, giving investors fresh numbers to assess Gartner stock after recent price moves. See our latest analysis for Gartner. Gartner...
NYSE:RXO
NYSE:RXOTransportation

RXO (RXO) Is Up 7.2% After Strong Brokerage Growth Narrows Losses - Has The Bull Case Changed?

In the past quarter, RXO, Inc. reported second-quarter 2026 results showing sales of US$1,774 million versus US$1,419 million a year earlier, with a net loss of US$9 million and basic and diluted loss per share from continuing operations unchanged at US$0.05. Despite a wider six-month net loss of US$45 million versus US$40 million a year earlier, RXO’s brokerage revenue growth and better-than-expected performance in brokerage and last-mile operations pointed to improving operating momentum...
NasdaqGS:SIGI
NasdaqGS:SIGIInsurance

Selective Insurance Group (SIGI) Leans On Efficiency Story, Does It Look Fairly Valued?

Why Selective Insurance Group Is On Investor Radar Today Selective Insurance Group (SIGI) is drawing investor attention after recent trading put its shares around $96.23, with performance figures available for the past week, month, past 3 months, year to date, and 1 year. See our latest analysis for Selective Insurance Group. Recent trading puts Selective Insurance Group’s share price at $96.23, with a 12.04% 90 day share price return and a 26.54% 1 year total shareholder return. This may...
NYSE:MTX
NYSE:MTXChemicals

How Investors Are Reacting To Minerals Technologies (MTX) Margin-Recovery Guidance After a Surprise Quarterly Loss

Minerals Technologies recently reported second-quarter 2026 results, with sales rising to US$548.4 million but swinging to a net loss of US$183.6 million, and followed this with full-year 2026 guidance calling for around US$75 million in quarterly operating income and earnings per share between US$1.55 and US$1.60. Management acknowledged near-term pressure but emphasized a planned recovery in operating margins above prior-year levels in the fourth quarter, underpinned by seasonality and...
NYSE:ELF
NYSE:ELFPersonal Products

e.l.f. Beauty (ELF) Lifts Guidance After Strong Earnings, Where Does Fair Value Sit?

What the latest guidance and earnings mean for e.l.f. Beauty stock e.l.f. Beauty (ELF) raised its fiscal 2027 net sales guidance to a range of US$1.94b to US$1.97b, alongside first quarter 2026 results that showed higher sales, net income and earnings per share year over year. The updated outlook now implies an 18% to 20% year over year net sales change for 2027, compared with a previously guided 12% to 14% range. This gives investors a clearer view of management’s current expectations for...
NasdaqGS:MSEX
NasdaqGS:MSEXWater Utilities

Middlesex Water (MSEX), Why Is Its Latest Update Drawing Attention?

Middlesex Water (MSEX) is in focus after reporting second quarter 2026 results, with sales of US$56.36 million and net income of US$14.77 million, both above the figures reported a year earlier. See our latest analysis for Middlesex Water. Middlesex Water’s recent earnings release has arrived alongside a firm share price recovery, with a 5.84% 1 month share price return, a 12.11% 3 month share price return and a 15.81% year to date share price return. The 1 year total shareholder return of...
NYSE:FLR
NYSE:FLRConstruction

Fluor (FLR) Is Up 13.6% After Raising 2026 Guidance On Backlog Surge And New Nuclear Hire – Has The Bull Case Changed?

Fluor Corporation reported past second-quarter 2026 results with sales of US$4,329 million and net income of US$114 million, while raising full-year adjusted EBITDA and operating cash flow guidance on the back of over US$6 billion in new awards that lifted backlog to about US$26.90 billion. Alongside these results, Fluor added retired U.S. Navy Admiral James F. (Frank) Caldwell Jr. to its board and key committees, underscoring the company’s emphasis on nuclear expertise and governance as it...
NasdaqGS:GRAL
NasdaqGS:GRALBiotechs

Did FDA’s Galleri PMA Panel Date Just Shift GRAIL's (GRAL) Multi‑Cancer Screening Narrative?

GRAIL announced that the FDA’s Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review its Premarket Approval application for the Galleri multi-cancer early detection blood test, which uses methylation patterns and artificial intelligence to detect cancer signals and predict their origin alongside existing screening methods. The PMA filing leans on extensive data from the PATHFINDER 2 study of 25,490 U.S. participants and over 70,000 participants from the NHS-Galleri...
NasdaqGS:IQ
NasdaqGS:IQEntertainment

iQIYI’s New Undercurrent Theater Short-Form Suspense Slate Could Be A Game Changer For iQIYI (IQ)

In early August 2026, iQIYI launched Undercurrent Theater, a horizontal short-form suspense drama brand featuring 10–25 minute, cinematic-quality episodes, now streaming on both its domestic and international platforms. By transplanting its Suspense Theater production discipline into a short-form format, iQIYI is aiming to turn premium micro-length suspense series into a distinct content brand that can stand apart from mainstream short-video platforms. We’ll now examine how building a...
NasdaqGS:CEG
NasdaqGS:CEGElectric Utilities

Constellation Energy (CEG) Lifted Guidance And Secured New Deals, Is It Still Undervalued?

Constellation Energy (CEG) has become a focus for investors after it raised full year adjusted operating earnings guidance and outlined new long term power purchase agreements, alongside regulatory progress on the Crane Clean Energy Center restart. See our latest analysis for Constellation Energy. Constellation Energy’s latest guidance increase and long term contracts come after a mixed year for investors, with the share price down 26.31% year to date but supported by a three year total...
NYSE:CNMD
NYSE:CNMDMedical Equipment

Is CONMED’s (CNMD) Earnings Beat And Higher Sales Outlook Reframing Its Core Investment Story?

In July 2026, CONMED Corporation reported past second-quarter 2026 results showing sales of US$343.49 million and net income of US$23.07 million, alongside higher basic and diluted earnings per share from continuing operations compared with a year earlier. For the first half of 2026, CONMED grew net income to US$36.90 million despite slightly lower sales, and marginally raised its full-year GAAP net sales guidance range to US$1.36 billion–US$1.37 billion. Now we’ll examine how this earnings...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

Why Nurix Therapeutics (NRIX) Is Back In The Spotlight

Nurix Therapeutics (NRIX) is in focus after enrolling the first patient in its global Phase 3 DAYBreak CLL-306 trial of BTK degrader bexobrutideg with Roche, alongside a separate $10 million milestone payment from Sanofi. See our latest analysis for Nurix Therapeutics. The latest clinical and partnership milestones appear to be feeding into building momentum in Nurix Therapeutics' stock, with a 90 day share price return of 56.82% and a 1 year total shareholder return of 159.45%. This...
NYSE:NNN
NYSE:NNNRetail REITs

Raised AFFO Guidance And 37th Dividend Hike Could Be A Game Changer For NNN REIT (NNN)

NNN REIT, Inc. recently reported its second-quarter 2026 results, showing revenue of US$244.27 million and net income of US$97.92 million, while also filing and completing follow-on common equity offerings and a broad shelf registration for multiple securities. Alongside this, the company raised its 2026 AFFO-per-share guidance, increased its quarterly dividend for the 37th consecutive year, and continued investing heavily in new properties while maintaining occupancy above 99%. With NNN...
NasdaqGS:ZG
NasdaqGS:ZGReal Estate

Does Q2 Loss And Leadership Shuffle At Zillow (ZG) Change The Bull Case For The Stock?

In early August 2026, Zillow Group, Inc. reported second-quarter 2026 results showing revenue of US$772 million and a quarterly net loss of US$4 million, alongside leadership changes including the elevation of CFO Jeremy Hofmann to Chief Operating Officer & Chief Financial Officer and the appointment of Cassandra Knight as Chief Legal and Policy Officer. These updates, together with the completion of a share repurchase program totaling US$3.48 billions since 2021, highlight Zillow’s focus on...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO

Sarepta Therapeutics recently narrowed its 2026 total net product revenue guidance to US$1.20 billion–US$1.30 billion and reported second-quarter 2026 revenue of US$401.25 million, down from US$611.09 million a year earlier, with a quarterly net loss of US$4.89 million. Alongside weaker quarterly results, the company is undergoing leadership change with Michael Severino, M.D., a veteran of AbbVie, Amgen, and Merck, stepping in as Chief Executive Officer and joining the Board, while Sarepta...
NYSE:POST
NYSE:POSTFood

Is Post Holdings (POST) Undervalued As Earnings Beat And Debt Reduction Takes Priority?

Post Holdings (POST) is back in focus after reporting third quarter fiscal 2026 results and updating investors on 2027 earnings expectations and capital allocation plans, including a clear tilt toward debt reduction instead of buybacks. See our latest analysis for Post Holdings. The latest earnings update and the decision to favour debt reduction over buybacks have come alongside a sharp reset in sentiment, with the share price down 12.79% on a 1 day basis and the 1 year total shareholder...
NYSE:CWK
NYSE:CWKReal Estate

Asia-Pacific Data Center Push Amid Softer Margins Could Be A Game Changer For Cushman & Wakefield (CWK)

Cushman & Wakefield recently reported past second-quarter 2026 results showing sales rising to US$2,762.6 million while net income eased to US$52.7 million, alongside continued expansion of its industrial advisory capabilities in California. At the same time, the firm has highlighted rapid growth in data center and logistics real estate activity in India and broader Asia-Pacific markets, underscoring its focus on higher-growth segments of commercial property services. We'll now explore how...
NYSE:MOG.A
NYSE:MOG.AAerospace & Defense

Can Moog (MOG.A) Justify Its Valuation As Earnings Beat And Guidance Rise?

Moog stock moves after earnings beat, guidance raise and acquisition plans Moog (MOG.A) drew fresh attention after reporting third quarter results with higher sales and net income year on year, raising full year guidance and outlining plans to pursue bolt on acquisitions. See our latest analysis for Moog. The earnings beat, higher guidance and fresh talk of bolt on acquisitions come after a strong run in Moog’s stock, with the share price up 61.33% year to date and the 1 year total...